Why the FDA Flags TRT Clinics: SARMs, Cure Claims, and Compounded Testosterone

If you run a testosterone clinic, the fastest way to draw an FDA warning letter is to market an unapproved product as if it were an approved drug, or to promise an outcome you cannot back up. In this vertical, three patterns do most of the damage: selling SARMs as “supplements” or “research compounds,” claiming testosterone or hormone therapy can cure or reverse a disease, and marketing compounded testosterone from a 503B outsourcing facility as if it were a routine, off-the-shelf prescription. Each one trips a specific legal definition, and each one has a safer way to say the same thing.

TL;DR

• SARMs are unapproved new drugs, not supplements. The FDA has repeatedly warned against marketing SARMs in body-building or performance products, and “for research use only” labels do not protect you [5].
• Cure, reverse, or treat language turns any product into a “drug.” Under the FD&C Act, an intended-use claim to treat disease is what defines a drug, regardless of what you call the product [2].
• Compounded testosterone is patient-specific, not a catalog item. 503B facilities have been cited for adulterated and misbranded sterile injectables, so marketing compounded testosterone as routine invites scrutiny.
• Outcome claims need evidence behind them, before you publish. The FTC expects competent and reliable support for health claims, and “deceptive” is judged by the net impression, not your fine print [1][4].
• Screen your copy first, then send it to your physician and counsel. A pre-screen catches the obvious triggers; your licensed reviewer and attorney are the final word.

Pattern 1: SARMs marketed as supplements or research compounds

This is the single most enforced pattern in the testosterone and performance space right now. Selective androgen receptor modulators (Ostarine/MK-2866, MK-677, Cardarine, and similar) are not approved drugs and are not legal dietary ingredients. When a clinic or affiliated store sells them, the FDA treats them as unapproved new drugs, full stop. The agency has issued a standing warning against using SARMs in body-building and performance products [5].

The labels people hope will save them do not. “For research use only,” “not for human consumption,” and “supplement” do not change the analysis when the surrounding marketing, dosing guidance, or customer base makes the real intended use obvious. In late 2025 the FDA sent warning letters to Atomix LLC, Prime Sports Nutrition, and Dynamic Health Group doing business as SARMS America, all for selling unapproved new drugs marketed as SARMs. The SARMS America letter named specific compounds including Ostarine MK-2866, MK-677, and Cardarine [3].

The safer way to phrase it: do not sell, bundle, or “recommend” SARMs at all, and do not let them appear in your content as a casual performance option. If a patient asks, the honest answer is that these are unapproved and not something a responsible clinic offers. Keep your marketing on FDA-approved testosterone formulations prescribed and supervised by a licensed provider.

Pattern 2: Cure, reverse, and disease-treatment claims

The word “drug” in federal law is defined largely by what you claim a product does. If your copy says testosterone or hormone therapy will cure, reverse, prevent, or treat a disease, you have made a drug claim, and the standard of proof jumps accordingly [2]. This is where clinics with completely legal, approved therapies still get into trouble: not because of the medicine, but because of the sentence.

Common triggers include “reverse low T permanently,” “cure erectile dysfunction,” “treat depression with hormones,” and “fix your metabolism.” Even softer phrasing like “restore your youth” or “beat aging” can create a deceptive net impression if the page implies an outcome you cannot support. The FTC judges the overall message a reasonable person takes away, and expects competent and reliable evidence behind health claims before they run [1][4]. A disclaimer in the footer does not rescue a headline that overpromises.

The safer way to phrase it: describe the therapy and the process, not a guaranteed cure. “We evaluate symptoms of low testosterone and, when clinically appropriate, prescribe physician-supervised testosterone therapy” is defensible. “Our program may help improve energy, libido, and mood for appropriate patients” is honest about variability. Keep claims tied to individualized clinical judgment, and let your physician decide what the evidence actually supports for your patient population.

Pattern 3: Compounded testosterone marketed as routine

Compounded testosterone has a legitimate place, but it is patient-specific by design. It exists for individuals who cannot use a commercially available product, and it is not an FDA-approved drug that has been tested for safety and efficacy the way manufactured formulations are. When marketing presents compounded testosterone as a standard, interchangeable, “order it today” product, it misstates what the patient is actually getting.

The supply side carries real risk too. In April 2025 the FDA cited Empower Clinic Services doing business as Empower Pharma, a 503B outsourcing facility, for adulterated and misbranded sterile testosterone cypionate [3]. If your clinic sources from an outsourcing facility, that facility’s compliance becomes part of your story, and language implying that compounded product is equivalent to an approved drug compounds the exposure.

The safer way to phrase it: be explicit that compounded medications are prepared for an individual patient based on a provider’s clinical decision, and that they are not FDA-approved products. Avoid implying interchangeability or routine availability. Know your 503B source, and let your provider, not your marketing page, frame when compounding is appropriate.

How to check your testosterone copy

Before any of this reaches your physician or your attorney, you can catch the obvious triggers yourself. Run your landing pages, ads, and intake emails through the free Claim Checker. It screens your wording against the same patterns regulators look for: drug claims on unapproved products, cure-or-reverse language, and overstated outcomes. It flags the sentences worth a second look so you are not sending raw copy into review.

To see what real enforcement looks like in this vertical, browse the TRT enforcement Atlas, where each entry links the actual warning letter and what triggered it. For the bigger picture across every health vertical, the pillar guide on the marketing claims that trigger FDA warning letters walks through the categories in detail.

One thing to be clear about: the Claim Checker is a screening and educational tool. It is not legal advice and it is not regulatory clearance. It helps you catch problems early, but your clinic’s own licensed physician and your counsel are the final gate on any substantive medical claim. We do not promise compliance, and no software can.

Frequently asked questions

Does labeling SARMs “for research use only” keep me out of trouble?

No. The FDA looks at the real intended use, which it infers from your marketing, dosing guidance, and customers, not just the disclaimer on the bottle. SARMs are unapproved new drugs, and the agency has warned specifically against using them in body-building and performance products [5]. The safest position is not to sell or recommend them at all.

Can I say testosterone therapy “reverses” low T or “cures” ED?

That phrasing creates a drug claim and a deceptive net impression, even when the underlying therapy is legitimate. Under federal law, claiming to cure, reverse, or treat a disease is part of what defines a product as a drug and raises the evidence bar [2][4]. Describe the clinical process and realistic, individualized outcomes instead of promising a cure.

Is compounded testosterone illegal to offer?

No, but it is patient-specific and not FDA-approved, so it cannot be marketed as a routine, interchangeable product. Outsourcing facilities have been cited for adulterated and misbranded sterile testosterone [3], so your 503B source and your wording both matter. Make clear that compounded medications are prepared for an individual patient based on a provider’s decision.

Will the Claim Checker make my copy compliant?

It will not, and nothing can promise that. The Claim Checker is a pre-screen that flags likely triggers so you can fix them before review. Your licensed physician and your attorney remain the final decision-makers on any substantive medical or regulatory claim.

Citations

1. Federal Trade Commission. Health Products Compliance Guidance. December 2022. https://www.ftc.gov/business-guidance/resources/health-products-compliance-guidance . Accessed June 8, 2026.
2. U.S. Food and Drug Administration. Federal Food, Drug, and Cosmetic Act, Section 201(g) (definition of “drug”). https://www.fda.gov/regulatory-information/laws-enforced-fda/federal-food-drug-and-cosmetic-act-fdc-act . Accessed June 8, 2026.
3. U.S. Food and Drug Administration. Warning Letters. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters . Accessed June 8, 2026.
4. Federal Trade Commission. Enforcement Authority (Section 5, deceptive or unfair acts). https://www.ftc.gov/about-ftc/mission/enforcement-authority . Accessed June 8, 2026.
5. U.S. Food and Drug Administration. FDA In Brief: FDA warns against using SARMs in body-building products. https://www.fda.gov/news-events/fda-brief/fda-brief-fda-warns-against-using-sarms-body-building-products . Accessed June 8, 2026.